XPhyto Provides Update on Integration of 3a-diagnostics GmbH - Seite 2

 

3a is a highly specialized German diagnostics company focused on development of innovative point-of-care test systems with a pipeline of proprietary oral biosensors for the real-time detection of bacterial and viral infectious diseases, including COVID-19, H1N1, and H5N1. Covid-ID Lab is a rapid RT-PCR test for the qualitative detection of SARS-CoV-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. To perform the test, Covid-ID Lab requires only a 20-minute PCR run time without prior RNA extraction as part of the sample preparation. The RT-PCR sample process detects the SARS-CoV-2 virus on a test chip within 5 minutes, when SARS-CoV-2 is present, the result can be read visually immediately. The target customers are airports, cruise lines, pharmacies, medical clinics, and any industrial or education site that requires rapid, definitive results.

 

Executive management of the holding company for 3a and Vektor is led by Prof. Dr. Beckert, also managing director of Vektor Pharma TF GmbH. Prof Dr. Beckert is a German-based scientist and experienced corporate executive who is leading XPhyto's drug formulation and diagnostics operations.

 

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

 

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.